Clinical Trial Failure Risk: The success of Gain Therapeutics' drug candidates is highly dependent on favorable results from ongoing and future clinical trials, which are inherently uncertain and prone to failure or delays.

Regulatory Approval Risk: Obtaining necessary regulatory approvals from agencies like the FDA or EMA is a lengthy, complex, and uncertain process, with no guarantee of approval for any drug candidate.

Capital Requirements Risk: Gain Therapeutics will require substantial additional capital to fund its research, development, and potential commercialization activities, and future financing may not be available on favorable terms or at all.